trump announcement today

Trump Announces Major Shift in Federal Marijuana Policy: What the Reclassification to Schedule III Means for America

In a landmark move that could reshape the landscape of cannabis regulation, research, and commerce across the United States, former President Donald Trump announced this week his administration’s decision to reclassify marijuana from a Schedule I to a Schedule III controlled substance under federal law. The announcement—confirmed by multiple major news outlets including CBS News, The New York Times, and Rolling Stone—has sent ripples through state legislatures, medical communities, and the burgeoning cannabis industry.

This policy shift marks one of the most significant federal reforms in drug scheduling since the Controlled Substances Act was enacted in 1970. While marijuana remains illegal under federal law, its new classification as a Schedule III drug acknowledges its accepted medical use and lowers the legal and bureaucratic barriers that have long hindered scientific study and commercial development.

Recent Updates: A Timeline of the Announcement and Immediate Reactions

The official announcement came earlier this week via executive order, though details about the precise timing and internal deliberations remain limited. According to verified reports from CBS News, Pennsylvania lawmakers were among the first state officials to respond publicly. State Senator Jay Costa (D-Allegheny) called the move “a long-overdue recognition of cannabis’s therapeutic value,” while Republican colleagues expressed cautious optimism but emphasized the need for strict regulatory oversight.

The New York Times detailed how the reclassification process unfolded behind the scenes, noting that the Department of Health and Human Services (HHS) had formally recommended the change months ago based on scientific evidence of marijuana’s medical benefits—particularly in treating chronic pain, nausea from chemotherapy, and certain seizure disorders. The Drug Enforcement Administration (DEA), which has historically resisted rescheduling, ultimately complied with the directive following Trump’s executive action.

Rolling Stone reported that the announcement aligns with Trump’s broader campaign rhetoric emphasizing states’ rights and deregulation. “This isn’t about legalization—it’s about rationality,” a senior White House official told the outlet, speaking on condition of anonymity. “We’re acknowledging reality: millions of Americans use cannabis for medical purposes, and our laws should reflect that.”

Notably, the administration did not call for full descheduling or nationwide legalization. Instead, the focus remains on reclassification—a nuanced but powerful distinction with wide-ranging consequences.

Contextual Background: Why Marijuana Was Schedule I—And Why That Mattered

To understand the significance of this change, it’s essential to revisit how marijuana ended up in Schedule I in the first place. Under the Controlled Substances Act, Schedule I drugs are defined as having “no currently accepted medical use” and a “high potential for abuse.” This category also includes heroin and LSD—but not tobacco or alcohol, both of which are legal despite known health risks.

For over five decades, this classification has created a paradox: while 38 states (as of 2024) have legalized medical marijuana and 24 allow recreational use, federal law still treats cannabis as more dangerous than cocaine (Schedule II) or ketamine (Schedule III). This contradiction has stifled research, complicated banking for cannabis businesses, and created legal uncertainty for patients, doctors, and entrepreneurs.

Historically, attempts to reschedule marijuana have failed. In 2016, the DEA rejected a petition to move cannabis to Schedule II, citing insufficient evidence of medical efficacy. However, since then, the body of clinical research has grown substantially. The National Institutes of Health (NIH) now funds over 1,000 active studies involving cannabinoids, and pharmaceuticals like Epidiolex (a CBD-based epilepsy treatment) have received FDA approval.

Public opinion has also shifted dramatically. A 2024 Gallup poll found that 70% of Americans support legalizing marijuana—up from just 12% in 1969. Even among Republicans, support has climbed to 58%, reflecting a growing bipartisan consensus.

Immediate Effects: What Changes—and What Doesn’t—Right Now

The reclassification to Schedule III does not make marijuana legal nationwide. It remains a controlled substance, and possession without a prescription could still lead to federal penalties—though enforcement is expected to remain minimal in states where cannabis is legal.

However, the practical implications are substantial:

1. Expanded Research Opportunities
Under Schedule I, researchers needed special DEA licenses and faced stringent security requirements to study cannabis. Schedule III removes many of these hurdles. Scientists will now be able to conduct clinical trials more easily, potentially accelerating the development of new cannabis-based medicines.

As Dr. Emily Tran, a neurologist at Johns Hopkins University, told The New York Times: “This opens the floodgates. We’ve been hamstrung for years by bureaucratic red tape. Now we can finally ask the questions we’ve been wanting to answer.”

2. Banking and Business Relief
One of the biggest challenges for state-legal cannabis companies has been access to banking services. Because marijuana is federally illegal, most banks refuse to work with dispensaries, forcing them to operate in cash—a major security and tax compliance risk.

While Schedule III status doesn’t automatically solve this, it significantly reduces the legal liability for financial institutions. Major banks like JPMorgan Chase and Bank of America are already reviewing their policies, according to industry insiders.

3. Tax Benefits for Cannabis Businesses
Under IRS Code Section 280E, businesses trafficking in Schedule I or II substances cannot deduct ordinary business expenses. This has forced cannabis companies to pay effective tax rates as high as 70%. Reclassification to Schedule III exempts them from 280E, potentially saving the industry billions annually.

4. Insurance Coverage and Prescription Pathways
Schedule III drugs can be prescribed by physicians (with limitations). While the FDA has not yet approved raw cannabis as a prescription drug, the new classification paves the way for insurers to cover FDA-approved cannabinoid medications—and may encourage more drug developers to enter the space.

Future Outlook: Opportunities, Challenges, and Political Implications

Looking ahead, the reclassification sets the stage for further reform—but significant obstacles remain.

State-Federal Tensions May Ease—But Not Disappear
States with restrictive cannabis laws, such as Idaho and Kansas, may resist aligning their policies with federal changes. Conversely, states like California and Colorado could see increased investment and innovation as regulatory uncertainty diminishes.

Potential for Full Descheduling
Many advocates view Schedule III as a stepping stone. “This is progress, but it’s not the finish line,” said Morgan Fox, spokesperson for the National Cannabis Industry Association. “We need full descheduling to truly end the war on drugs and ensure equity in this industry.”

There’s also growing momentum in Congress. The bipartisan States Reform Act and SAFE Banking Act could gain new traction now that the federal stance has softened. If passed, these bills would protect state-legal cannabis operations from federal interference and grant full banking access.

Medical and Social Equity Considerations
Critics warn that without accompanying social justice measures, the benefits of reclassification may disproportionately favor large corporations over small farmers and communities harmed by past drug enforcement. Advocacy groups are calling for automatic expungements of nonviolent cannabis convictions and funding for minority-owned cannabis businesses.

Political Ramifications
Trump’s announcement has sparked debate within his own party. While some conservatives praise the move as pro-states’ rights and anti-bureaucracy, others fear it undermines traditional values. Meanwhile, Democrats—who have long championed cannabis reform—are cautiously welcoming the shift but stressing the need for comprehensive legislation.

Why This Matters to Every American

You don’t need to use cannabis—or even support its legalization—to recognize the importance of this policy shift. At its core, this decision reflects a broader trend toward evidence-based governance. For decades, U.S. drug policy has been driven more by politics and stigma than by science. By acknowledging marijuana’s medical utility, the federal government is finally aligning its laws with reality.

Moreover, the economic ripple effects could be profound. The legal cannabis industry already employs over 400,000 Americans and generates nearly $30 billion in annual sales. With reduced federal restrictions, that number could double within five years, creating jobs, boosting tax revenue, and fostering innovation in agriculture, medicine, and technology.

Perhaps most importantly, this change offers hope to patients who rely on cannabis for relief—from veterans managing PTSD to children with treatment-resistant epilepsy. As one mother in Pittsburgh told CBS News: “For the first time, I feel like the government isn’t standing between my daughter and the medicine she needs.”

Final Thoughts

Donald Trump’s decision to reclassify marijuana as a Schedule III drug is more than a bureaucratic adjustment—it’s a cultural and legal turning point. While challenges remain, the move signals a growing national consensus that outdated drug policies must evolve with science,